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Follicular lymphoma is an indolent, or slow-growing, lymphoma of follicular B cells, and is the second 
most common form of non-Hodgkin’s lymphoma. At the time of diagnosis, 85% of patients with FL 
have widespread disease and are considered incurable by conventional therapies. Over the last 15 
years, treatment approaches using various combinations of chemotherapy and immunotherapy have 
drastically improved patient survival. However, there is no consensus on the best frontline treatment 
regimen. Immunotherapy uses monoclonal antibodies directed against the cell surface protein CD20 
that is found on both normal and malignant B cells. Antibody binding to CD20 activates the immune 
system to attack and kill the cancerous B cells, and makes these cells more susceptible to 
chemotherapy. Attaching a radioactive isotope to the antibody allows targeted delivery of radiation to 
the cancerous cell. To compare the efficacy of two different anti-CD20 antibodies, a phase III trial 
randomized FL patients using a frontline chemotherapy regimen with either unlabeled rituximab or 
Iodine-131 (
131
I) radiolabeled-tositumomab was carried out and found the two regimens equally 
efficacious. 
 Drs. Oliver Press, Ajay Gopal, and David Maloney of the Clinical Research Division and Dr. Michael 
LeBlanc and Joseph Unger of the Public Health Sciences Division contributed to this Southwest 
Oncology Group (SWOG) and Cancer and Leukemia Group B phase III trial (SWOG S0016). 
Previous sequential phase II studies examined various frontline FL treatment regimens; the current 
study is an extension of protocol SWOG S9911. Between March 1, 2001 and September 15, 2008, 
554 patients with previously untreated, advanced FL were enrolled. All patients received 
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) every 21 days for six cycles. 
The arm with CHOP alone was closed in December 15, 2002 with only 17 patients after trial results 
from another study demonstrated that the addition of rituximab markedly improved both progression-
free survival and overall survival. The remaining patients were randomized to either CHOP plus six 
doses of rituximab administered during and after chemotherapy (CHOP-R, n=267), or CHOP 
followed by consolidation tositumomab/
131
I-tositumomab therapy after 4-8 weeks (CHOP-RIT, 
n=265). 
 Rituximab leads to B cell death through a variety of mechanisms, including antibody-dependent 
cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis of CD20-positive cells. 
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tositumomab has the added benefit of targeted delivery of radiation to CD20-positive cells to further 
eliminate cancerous cells disseminated throughout the body. The two-year and five-year estimates 
of progression-free survival were equally good for the CHOP-R and CHOP-RIT arms 
(76% versus 80%, P=0.11; 60%versus 66%, P=0.05) after a median follow-up of 4.9 years. The two-
year and five-year estimates of overall survival were also equivalent for the two treatment arms, 97% 
and 92% on CHOP-R and 93% and 86% on CHOP-RIT (P=0.08). 
The side effects and toxicities were similar for both CHOP-R and CHOP-RIT, and included mostly 
hematologic events typical of CHOP therapy. CHOP-R patients had more severe febrile neutropenia, 
or fevers (16% versus 10%, P<0.05), as found in previous studies. More thrombocytopenia was 
observed with RIT (18% versus 2%, P<0.0001), as was hypothyroidism (7% versus 3%,P<0.07) and 
HAMA (human anti-murine antibody) formation (17% versus 2%, P<0.06), as expected with RIT 
although it did not reach significance. Secondary malignancies are a major concern with the 
radiolabeled antibodies; however, the incidence of secondary malignancies was similar for CHOP-R 
and CHOP-RIT at the last follow-up point (9% versus 8%). 
While both therapies treat frontline FL with a similar level of efficacy, a combined strategy of CHOP-
R followed by RIT could be superior and warrants future trials. Importantly, follow-up of the phase II 
CHOP-RIT trial (SWOG S9911) currently has a 10-year progression-free survival rate of 60%, and 
findings suggest that immunochemotherapy may prevent the relapse of disease and cure a subset of 
advanced stage FL patients previously thought to be incurable. 
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Rituximab and Iodine-131-tositumomab are 
monoclonal antibodies that recognize the CD20 
cell surface protein on normal and malignant B 
cells in follicular non-Hodgkin’s lymphoma. 
Antibody binding to CD20 activates the immune 
system to attack and kill the cancerous B cells, 
and makes the cells more susceptible to 
chemotherapy. Iodine-131-tositumomab also 
targets radiation to the malignant B cells. 
 
